Chronic Myelomonocytic Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CMML MCID: CHR285 MIFTS: 59	Chronic Myelomonocytic Leukemia (CMML) Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Chronic Myelomonocytic Leukemia

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵ ¹⁴ ³⁶ ¹⁶

Leukemia, Myelomonocytic, Chronic ¹⁹ ⁷¹

Chronic Myelomonocytic Leukaemia Without Mention of Remission ³³

Cmml - [chronic Myelomonocytic Leukaemia] ³³

Leukemia Myelomonocytic Chronic ⁵³

Chronic Monocytoid Leukaemia ³³

Chronic Monocytic Leukaemia ³³

Cmml ⁵⁸

Characteristics:

Prevelance:

1-9/1000000 (Europe) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Monocytic leukaemia

Chronic myelomonocytic leukaemia

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Myelodysplastic and myeloproliferative neoplasms

Chronic myelomonocytic leukaemia

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:0080188

NCIt ⁴⁹ C3178

ICD10 ³¹ C93.1

MESH via Orphanet ⁴⁴ D015477

ICD10 via Orphanet ³² C93.1

UMLS via Orphanet ⁷² C0023480

Orphanet ⁵⁸ ORPHA98823

EFO ¹⁶ EFO_1001779

ICD11 ³³ 2073226578

UMLS ⁷¹ C0023480

Sources

Summaries for Chronic Myelomonocytic Leukemia

GARD: ¹⁹ A rare myelodysplastic/myeloproliferative neoplasm characterized by a spectrum of clinical, hematological, and morphological features, ranging from predominantly myelodysplastic to mainly myeloproliferative in nature. Infiltration of the liver, spleen, lymph nodes, and other organs is common. Persistent peripheral blood monocytosis with monocytes accounting for more than 10% of leukocytes is the hallmark of the condition. Blasts constitute less than 20% of the cells in the peripheral blood and bone marrow. Other abnormalities are variable. Patients may present with constitutional symptoms, signs and symptoms of hematopoietic insufficiency, and hepatosplenomegaly. The disease is associated with a risk of transformation to acute myeloid leukemia.

MalaCards based summary: Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to juvenile myelomonocytic leukemia and myelodysplastic syndrome, and has symptoms including fatigue, fever and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Disease and Akt Signaling. The drugs homoharringtonine and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and monocytes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Orphanet: ⁵⁸ A rare myelodysplastic/myeloproliferative neoplasm characterized by a spectrum of clinical, hematological, and morphological features, ranging from predominantly myelodysplastic to mainly myeloproliferative in nature. Infiltration of the liver, spleen, lymph nodes, and other organs is common. Persistent peripheral blood monocytosis with monocytes accounting for more than 10% of leukocytes is the hallmark of the condition. Blasts constitute less than 20% of the cells in the peripheral blood and bone marrow. Other abnormalities are variable. Patients may present with constitutional symptoms, signs and symptoms of hematopoietic insufficiency, and hepatosplenomegaly. The disease is associated with a risk of transformation to acute myeloid leukemia.

Disease Ontology: ¹¹ A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

Wikipedia: ⁷⁵ Chronic myelomonocytic leukemia (CMML) is a type of leukemia, which are cancers of the blood-forming... more...

Sources

Related Diseases for Chronic Myelomonocytic Leukemia

Diseases in the Acute Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)

#	Related Disease	Score	Top Affiliating Genes
1	juvenile myelomonocytic leukemia	32.7	U2AF1 TET2 SRSF2 SETBP1 RUNX1 PTPN11
2	myelodysplastic syndrome	32.3	U2AF1 TOP1 TET2 SRSF2 SETBP1 RUNX1
3	myelodysplastic/myeloproliferative neoplasm	32.2	U2AF1 TET2 SRSF2 SETBP1 PTPN11 PDGFRB
4	leukemia	32.2	U2AF1 RUNX1 PTPN11 PDGFRB NF1 KIT
5	refractory anemia	31.8	TET2 ASXL1
6	myeloproliferative neoplasm	31.8	U2AF1 TET2 SRSF2 RUNX1 PTPN11 PDGFRB
7	leukemia, acute myeloid	31.7	U2AF1 TOP1 TET2 SRSF2 SETBP1 RUNX1
8	acute leukemia	31.6	TOP1 SETBP1 RUNX1 KIT JAK2 GATA2
9	myeloid leukemia	31.5	U2AF1 TET2 SETBP1 RUNX1 PTPN11 PDGFRB
10	refractory anemia with excess blasts	31.5	U2AF1 TET2 SETBP1 GATA2 ASXL1
11	thrombocytopenia	31.5	U2AF1 TOP1 RUNX1 PTPN11 KIT JAK2
12	acute myelomonocytic leukemia	31.4	RUNX1 KIT FLT3 ETV6 CSF1
13	hypereosinophilic syndrome	31.4	PDGFRB KIT JAK2 CSF2
14	hematologic cancer	31.4	U2AF1 TOP1 RUNX1 PTPN11 PDGFRB KIT
15	leukemia, chronic myeloid	31.4	U2AF1 TET2 SETBP1 RUNX1 PTPN11 PDGFRB
16	mastocytosis	31.4	TET2 SRSF2 PDGFRB KIT JAK2 FLT3
17	myelofibrosis	31.4	U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
18	systemic mastocytosis	31.3	U2AF1 TET2 SRSF2 PTPN11 PDGFRB KIT
19	pancytopenia	31.3	U2AF1 RUNX1 KIT FLT3 CSF2 CSF1
20	aplastic anemia	31.3	U2AF1 GATA2 FLT3 CSF3R CSF2 CSF1
21	atypical chronic myeloid leukemia, bcr-abl1 negative	31.3	U2AF1 TET2 SRSF2 SETBP1 PDGFRB JAK2
22	neutropenia	31.2	TOP1 PTPN11 JAK2 FLT3 CSF3R CSF2
23	thrombocytosis	31.2	U2AF1 TET2 JAK2 CSF2 ASXL1
24	deficiency anemia	31.2	U2AF1 KIT JAK2 FLT3 CSF3R CSF2
25	polycythemia vera	31.2	U2AF1 TET2 PTPN11 PDGFRB KIT JAK2
26	chronic neutrophilic leukemia	31.1	U2AF1 TET2 SRSF2 SETBP1 JAK2 CSF3R
27	neutrophilia, hereditary	31.1	U2AF1 JAK2 FLT3 CSF3R CSF2
28	leukemia, chronic lymphocytic	31.1	U2AF1 TET2 SRSF2 PTPN11 KIT JAK2
29	essential thrombocythemia	31.1	U2AF1 TET2 SRSF2 SETBP1 KIT JAK2
30	leukemia, acute lymphoblastic	31.1	U2AF1 TOP1 RUNX1 PTPN11 KIT JAK2
31	mastocytosis, cutaneous	31.0	U2AF1 TET2 SRSF2 KIT ASXL1
32	myeloma, multiple	31.0	U2AF1 TET2 PTPN11 NF1 JAK2 FLT3
33	myeloid sarcoma	31.0	U2AF1 KIT FLT3
34	leukemia, acute monocytic	31.0	U2AF1 FLT3 CSF1
35	chronic leukemia	30.9	U2AF1 TET2 SRSF2 SETBP1 PDGFRB KIT
36	platelet disorder, familial, with associated myeloid malignancy	30.9	RUNX1 ETV6
37	wilms tumor 1	30.9	U2AF1 TET2 NF1 KIT FLT3 CSF2
38	refractory cytopenia with multilineage dysplasia	30.9	U2AF1 TET2 SETBP1 GATA2 ASXL1
39	b-lymphoblastic leukemia/lymphoma	30.9	U2AF1 KIT FLT3 ETV6
40	langerhans cell histiocytosis	30.8	U2AF1 CSF2 CSF1
41	connective tissue disease	30.8	U2AF1 TOP1 NF1 KIT JAK2 CSF2
42	blood platelet disease	30.8	U2AF1 TET2 SRSF2 RUNX1 KIT JAK2
43	acute promyelocytic leukemia	30.7	U2AF1 TET2 RUNX1 KIT GATA2 FLT3
44	peripheral nervous system disease	30.7	U2AF1 TOP1 NF1 KIT JAK2 CSF2
45	rasopathy	30.7	U2AF1 SETBP1 PTPN11 PDGFRB NF1 KIT
46	vexas syndrome	30.7	U2AF1 TET2 ASXL1
47	systemic mastocytosis with associated hematologic neoplasm	30.6	TET2 SRSF2 KIT ASXL1
48	immunodeficiency 21	30.6	U2AF1 SETBP1 GATA2 FLT3 ASXL1
49	myeloproliferative disorder, chronic, with eosinophilia	30.6	PDGFRB ETV6
50	paroxysmal nocturnal hemoglobinuria	30.6	U2AF1 FLT3 CSF3R CSF2

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:

Sources

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

UMLS symptoms related to Chronic Myelomonocytic Leukemia:

fatigue; fever; night sweats

GenomeRNAi Phenotypes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

²⁵ (show all 27)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	9.84	CSF3R
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	9.84	CSF1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.84	U2AF1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	9.84	CSF3R
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-136	9.84	CSF3R TOP1 U2AF1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-139	9.84	CSF3R
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-146	9.84	CSF3R
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-148	9.84	CSF3R
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.84	CSF1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	9.84	KIT
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	9.84	U2AF1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.84	KIT
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-164	9.84	CSF3R
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.84	CSF3R
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-170	9.84	CSF1 KIT
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	9.84	CSF1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	9.84	CSF2
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.84	CSF2 CSF3R U2AF1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	9.84	KIT
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-38	9.84	TOP1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-61	9.84	KIT
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	9.84	CSF2
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.84	KIT U2AF1
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-89	9.84	U2AF1
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	9.84	KIT
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	9.84	U2AF1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	9.84	KIT

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

⁴⁵ (show all 21)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.43	ASXL1 CSF1 CSF2 ETV6 FLT3 GATA2
2	endocrine/exocrine gland	MP:0005379	10.43	ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
3	growth/size/body region	MP:0005378	10.41	ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
4	neoplasm	MP:0002006	10.38	ASXL1 CSF2 ETV6 FLT3 HIP1 JAK2
5	cellular	MP:0005384	10.38	ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
6	nervous system	MP:0003631	10.32	CSF1 CSF2 CSF3R GATA2 HIP1 JAK2
7	immune system	MP:0005387	10.31	ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
8	cardiovascular system	MP:0005385	10.3	CSF1 CSF2 CSF3R ETV6 GATA2 JAK2
9	normal	MP:0002873	10.29	ETV6 GATA2 HIP1 JAK2 KIT NF1
10	liver/biliary system	MP:0005370	10.27	ASXL1 CSF1 ETV6 HIP1 JAK2 KIT
11	behavior/neurological	MP:0005386	10.21	ASXL1 CSF1 CSF2 HIP1 JAK2 KIT
12	embryo	MP:0005380	10.16	CSF2 ETV6 GATA2 JAK2 KIT NF1
13	no phenotypic analysis	MP:0003012	10.13	CSF1 ETV6 FLT3 KIT PTPN11 RUNX1
14	hematopoietic system	MP:0005397	10.09	ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
15	craniofacial	MP:0005382	10.04	ASXL1 CSF1 CSF2 KIT NF1 PDGFRB
16	skeleton	MP:0005390	10.03	ASXL1 CSF1 CSF2 ETV6 FLT3 HIP1
17	hearing/vestibular/ear	MP:0005377	10.02	CSF1 GATA2 KIT NF1 PTPN11 U2AF1
18	reproductive system	MP:0005389	10.02	CSF1 CSF2 CSF3R GATA2 HIP1 JAK2
19	respiratory system	MP:0005388	9.97	CSF1 CSF2 HIP1 JAK2 KIT NF1
20	mortality/aging	MP:0010768	9.93	ASXL1 CSF1 CSF2 CSF3R ETV6 FLT3
21	integument	MP:0010771	9.32	CSF1 CSF2 ETV6 JAK2 KIT NF1

Sources

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

homoharringtonine

Phase 4

3628

Daunorubicin

Approved

Phase 3

20830-81-3

30323

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Aldesleukin

Approved

Phase 3

110942-02-4

Allopurinol

Approved

Phase 3

315-30-0

2094 135401907

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Hydroxyurea

Approved

Phase 3

127-07-1

3657

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Busulfan

Approved, Investigational

Phase 3

55-98-1

2478

Etoposide

Approved

Phase 3

33419-42-0

36462

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Tioguanine

Approved

Phase 3

154-42-7

2723601

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Fluconazole

Approved, Investigational

Phase 3

86386-73-4

3365

Caspofungin

Approved

Phase 3

179463-17-3, 162808-62-0

2826718

Lenalidomide

Approved

Phase 3

191732-72-6

216326

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Lonafarnib

Approved, Investigational

Phase 3

193275-84-2

148195

Tacrolimus

Approved, Investigational

Phase 3

104987-11-3

6473866 445643

Aspartic acid

Approved, Nutraceutical

Phase 3

56-84-8

5960

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Pevonedistat

Investigational

Phase 3

905579-51-3

49831043

Anti-Infective Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Hormones

Phase 3

Antifungal Agents

Phase 3

Hormone Antagonists

Phase 3

Antiemetics

Phase 3

glucocorticoids

Phase 3

Anti-Inflammatory Agents

Phase 3

BB 1101

Phase 3

Gastrointestinal Agents

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Anti-Retroviral Agents

Phase 3

Interleukin-2

Phase 3

Anti-HIV Agents

Phase 3

Analgesics, Non-Narcotic

Phase 3

Emetics

Phase 3

Etoposide phosphate

Phase 3

16760419

ON 01910

Phase 3

N-Methylaspartate

Phase 3

Hydrocortisone-17-butyrate

Phase 3

Interventional clinical trials:

(show top 50) (show all 298)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial	Recruiting	NCT03873311	Phase 4	Azacytidine, HAG Regimen;Azacytidine
2	Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study	Unknown status	NCT00043134	Phase 3	decitabine
3	A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents	Completed	NCT02907359	Phase 3	Guadecitabine
4	A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)	Completed	NCT02214407	Phase 3	Decitabine;HYDROXYUREA
5	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
6	Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine	Completed	NCT01928537	Phase 3	rigosertib sodium
7	A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)	Completed	NCT00002798	Phase 3	asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
8	Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine	Completed	NCT01241500	Phase 3	ON 01910.Na
9	A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation	Completed	NCT01305200	Phase 3	supersaturated calcium phosphate rinse
10	Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years	Completed	NCT00006363	Phase 3	cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
11	A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)	Completed	NCT01307579	Phase 3	Caspofungin Acetate;Fluconazole
12	A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)	Recruiting	NCT04256317	Phase 2, Phase 3	Azacitidine;ASTX030 (cedazuridine + azacitidine);Cedazuridine
13	Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)	Recruiting	NCT05153226	Phase 3	Cyclophosphamide
14	A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)	Active, not recruiting	NCT04266301	Phase 3	MBG453;Azacitidine;Placebo
15	A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)	Active, not recruiting	NCT03306264	Phase 3	ASTX727;Dacogen
16	A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia	Active, not recruiting	NCT03268954	Phase 3	Azacitidine;Pevonedistat
17	A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA	Active, not recruiting	NCT04842604	Phase 3	Glasdegib;Azacitidine
18	Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid�) Alone and in Combination With Epoetin Alfa (Procrit�) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia	Active, not recruiting	NCT00843882	Phase 3	Lenalidomide
19	A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia	Terminated	NCT00109538	Phase 3	Lonafarnib
20	Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis	Terminated	NCT01749111	Phase 3	ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
21	A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)	Unknown status	NCT03040401	Phase 1, Phase 2	Cohort 1, Ceplene® and Proleukin®;Cohort 2, Ceplene® and Proleukin®;Cohort 3, Ceplene® and Proleukin®
22	A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia	Unknown status	NCT01368757	Phase 1, Phase 2	Revlimid
23	A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q	Unknown status	NCT00885508	Phase 2	Lenalidomide
24	A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of Mutation TP53 (TP53) Mutant Myeloid Neoplasms	Unknown status	NCT03588078	Phase 1, Phase 2	APR-246;Azacitidine
25	Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure	Unknown status	NCT01133886	Phase 2	Decitabine
26	Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability	Unknown status	NCT01404741	Phase 2
27	A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity	Completed	NCT01776723	Phase 1, Phase 2	Ruxolitinib
28	An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)	Completed	NCT01736683	Phase 2	Sotatercept
29	A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	Completed	NCT00451048	Phase 2	sunitinib malate
30	A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia	Completed	NCT02610777	Phase 2	Azacitidine;Pevonedistat
31	Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)	Completed	NCT00381550	Phase 2	fludarabine phosphate;triapine
32	A Pilot Study of the Safety and Efficacy of Imatinib in Reducing Monocytosis or Leukocytosis in Patients With Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia, Respectively	Completed	NCT00079313	Phase 2	Imatinib
33	A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).	Completed	NCT00946647	Phase 1, Phase 2	Panobinostat (LBH589);5-Azacytidine
34	A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia	Completed	NCT02807272	Phase 2	Tipifarnib
35	A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia	Completed	NCT00136409	Phase 2	Imatinib mesylate
36	A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia	Completed	NCT00313586	Phase 2	Azacitidine;Entinostat
37	A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia	Completed	NCT02323178	Phase 1, Phase 2	eltrombopag
38	A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia	Completed	NCT01098084	Phase 2	Decitabine
39	A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia	Completed	NCT01251627	Phase 2	Decitabine
40	A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML)	Completed	NCT01235117	Phase 2	azacitidine
41	A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML)	Completed	NCT01350947	Phase 2	5-Azacitidine
42	A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response	Completed	NCT02197676	Phase 2	SGI-110 administration
43	Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft	Completed	NCT02556931	Phase 2	Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44	A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)	Completed	NCT00860574	Phase 2	treosulfan;fludarabine phosphate;tacrolimus;methotrexate
45	A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies	Completed	NCT00462605	Phase 2	entinostat;sargramostim
46	A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome	Completed	NCT02666950	Phase 2	Cytarabine;WEE1 Inhibitor AZD1775
47	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
48	Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial	Completed	NCT00397813	Phase 2	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
49	Very Low-dose Total Body Irradiation in Combination With Total Lymphoid Irradiation and Anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-Myeloablative Hematopoietic Cell Transplantation	Completed	NCT03734601	Phase 2	Anti-thymocyte globulin (ATG);Tacrolimus;Mycophenolate mofetil (MMF)
50	A Feasibility Study of "Early" Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms	Completed	NCT02756572	Phase 2	Cladribine;Cyclosporine;Cytarabine;Fludarabine Phosphate;Melphalan;Mitoxantrone Hydrochloride;Mycophenolate Mofetil;Sirolimus;Melphalan Hydrochloride

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:

Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution

Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:

Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244

Sources

Genetic Tests for Chronic Myelomonocytic Leukemia

Genetic tests related to Chronic Myelomonocytic Leukemia:

#	Genetic test	Affiliating Genes
1	Chronic Myelomonocytic Leukemia ²⁸

Sources

Anatomical Context for Chronic Myelomonocytic Leukemia

Organs/tissues related to Chronic Myelomonocytic Leukemia:

MalaCards : Bone Marrow, Myeloid, Monocytes, Bone, Spleen, Liver, Nk Cells

Sources

Publications for Chronic Myelomonocytic Leukemia

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 2317)

#	Title	Authors	PMID	Year
1	ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. ⁵	Falchi L...Verstovsek S	24854988	2014
2	Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia. ⁵	Chonabayashi K...Takaori-Kondo A	23873282	2014
3	Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. ⁵	Walz C...Reiter A	21705501	2011
4	The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation. ⁵	Vu HA...Sato Y	19345670	2009
5	FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. ⁵	Vu HA...Sato Y	16761019	2006
6	RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. ⁵³ ⁶²	Kuo MC...Shih LY	19282830	2009
7	Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. ⁵³ ⁶²	Dobbin E...Wheadon H	19100521	2009
8	Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. ⁵³ ⁶²	Fend F...Orazi A	18555525	2008
9	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. ⁵³ ⁶²	Gelsi-Boyer V...Chaffanet M	18925961	2008
10	Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. ⁵³ ⁶²	Oki Y...Issa JP	18055864	2008
11	FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. ⁵³ ⁶²	Lee BH...Gilliland DG	17936561	2007
12	The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. ⁵³ ⁶²	Hsieh PP...Chang CC	17643100	2007
13	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. ⁵³ ⁶²	Quintas-Cardama A...Cortes J	16955510	2006
14	Atypical myeloproliferative disorders: diagnosis and management. ⁵³ ⁶²	Tefferi A...Pardanani A	16610578	2006
15	JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. ⁵³ ⁶²	Jelinek J...Issa JP	16037387	2005
16	Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. ⁵³ ⁶²	Loh ML...Tartaglia M	15725481	2005
17	Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. ⁵³ ⁶²	Gotlib J	15995322	2005
18	Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. ⁵³ ⁶²	Beran M	15068895	2004
19	Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. ⁵³ ⁶²	George D	12908555	2003
20	Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. ⁵³ ⁶²	Ramshaw HS...Lopez AF	12384142	2002
21	Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. ⁵³ ⁶²	Magnusson MK...Dunbar CE	11588050	2001
22	Regulation of the Src homology 2-containing inositol 5-phosphatase SHIP1 in HIP1/PDGFbeta R-transformed cells. ⁵³ ⁶²	Saint-Dic D...Ross TS	11287412	2001
23	Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells. ⁵³ ⁶²	Hagiwara S...Yuo A	11372744	2001
24	Protease inhibitor 10 inhibits tumor necrosis factor alpha -induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes. ⁵³ ⁶²	Schleef RR...Chuang TL	10871600	2000
25	Thrombopoietin and myelodysplastic syndromes. ⁵³ ⁶²	Ogata K...Tamura H	11039665	2000
26	Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. ⁵³ ⁶²	Yalman N...Gedikoglu G	11105617	2000
27	Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. ⁵³ ⁶²	Cortes J...Kantarjian H	10784392	2000
28	Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. ⁵³ ⁶²	Hasegawa Y...Nagasawa T	10784404	2000
29	Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. ⁵³ ⁶²	Ross TS...Gilliland DG	10428802	1999
30	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. ⁵³ ⁶²	Frankel AE...Eaves C	9834234	1998
31	Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). ⁵³ ⁶²	Ross TS...Gilliland DG	9616134	1998
32	Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta). ⁵³ ⁶²	Bourgeade MF...Cayre YE	9558390	1998
33	Analysis of the granulocyte colony-stimulating factor receptor gene structure using PCR-SSCP in myeloid leukemia and myelodysplastic syndrome. ⁵³ ⁶²	Shibata S...Niho Y	9548419	1998
34	Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193. ⁵³ ⁶²	Riewald M...Schleef RR	9454755	1998
35	Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG. ⁵³ ⁶²	Urban C...Burdach S	9180913	1997
36	Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. ⁵³ ⁶²	Hasle H...Tommerup N	9042140	1997
37	The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. ⁵³ ⁶²	Carroll M...Gilliland DG	8962143	1996
38	The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. ⁵³ ⁶²	Matsumura I...Kanakura Y	9031083	1996
39	ETV6 gene rearrangements in hematopoietic malignant disorders. ⁵³ ⁶²	Wlodarska I...van den Berghe H	9031109	1996
40	Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. ⁵³ ⁶²	Beran M...Estey E	8839838	1996
41	Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. ⁵³ ⁶²	Geissler K...Lechner K	8879210	1996
42	Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. ⁵³ ⁶²	Drexler HG...Quentmeier H	8751457	1996
43	Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. ⁵³ ⁶²	Yamamoto M...Wada H	8756090	1996
44	In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels. ⁵³ ⁶²	Zwierzina H...Geissler D	9816264	1996
45	bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia. ⁵³ ⁶²	Crisan D...Wilner F	8818385	1996
46	Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. ⁵³ ⁶²	Nagata H...Metcalfe DD	7479840	1995
47	The levels of granulocyte colony-stimulating factor in the plasma of the bone marrow aspirate in various hematological disorders. ⁵³ ⁶²	Shinohara K...Tachibana K	7549901	1995
48	Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. ⁵³ ⁶²	Golub TR...Gilliland DG	7761424	1995
49	Exon trap analysis of a NF1 splice-site mutation in a chronic myelomonocytic leukemia patient. ⁵³ ⁶²	Ludwig L...Bartram CR	7769857	1995
50	Prognostic value of c-mpl expression in myelodysplastic syndromes. ⁵³ ⁶²	Bouscary D...Dreyfus F	7539513	1995

Sources

Genes for Chronic Myelomonocytic Leukemia

Genes related to Chronic Myelomonocytic Leukemia (4 elite genes):

(show top 50) (show all 70)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ETV6	ETS Variant Transcription Factor 6	Protein Coding	416.62	Gene fusion ⁵⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Functions (show sections)	8168137 7742547 19345670 (more) 21705501 23873282 16761019 24854988 9031109 7761424
2	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	382.4	Gene fusion ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	8168137 7742547 11588050 (more) 9616134 12908555 19100521 7761424 9653143 10428802 15995322 11287412 8962143 9558390
3	ASXL1	ASXL Transcriptional Regulator 1	Protein Coding	61.4	Candidate gene tested ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)	31723789
4	SRSF2	Serine And Arginine Rich Splicing Factor 2	Protein Coding	33.26	Candidate gene tested ⁵⁸ DISEASES inferred ¹⁴	31723789
5	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	48.46	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19345670 21705501 23873282 (more) 16761019 24854988 17936561
6	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	31.57	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
7	RUNX1	RUNX Family Transcription Factor 1	Protein Coding	28.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	19282830 18925961 8049440
8	HIP1	Huntingtin Interacting Protein 1	Protein Coding	26.38	Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	9616134 10428802 11287412
9	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	26.22	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
10	SETBP1	SET Binding Protein 1	Protein Coding	25.01	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
11	JAK2	Janus Kinase 2	Protein Coding	23.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16037387 18555525 17643100 (more) 18055864
12	GATA2	GATA Binding Protein 2	Protein Coding	22.88	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
13	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	21.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7479840
14	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	20.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9548419
15	NF1	Neurofibromin 1	Protein Coding	19.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7769857 9042140
16	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	19.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15725481
17	CSF2	Colony Stimulating Factor 2	Protein Coding	18.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9834234 12384142
18	CSF1	Colony Stimulating Factor 1	Protein Coding	17.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7682464 11372744 10784404 (more) 8879210
19	TOP1	DNA Topoisomerase I	Protein Coding	17.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10784392 16955510 8839838 (more) 15068895
20	LOC107197952	NUP98-HOXA9 Recombination Region	Functional Element	17.07	GeneCards inferred via : Publications Summaries (show sections)
21	USP16	Ubiquitin Specific Peptidase 16	Protein Coding	16.52	GeneCards inferred via : Disorders Publications (show sections)
22	CSF1R	Colony Stimulating Factor 1 Receptor	Protein Coding	16.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2406720
23	MPL	MPL Proto-Oncogene, Thrombopoietin Receptor	Protein Coding	13.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7773160 9031083 8751457 (more) 11039665 7539513
24	SERPINB10	Serpin Family B Member 10	Protein Coding	13.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9454755 10871600
25	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	12.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16610578 15995322
27	CSF3	Colony Stimulating Factor 3	Protein Coding	11.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9180913 7549901 11105617
28	RABEP1	Rabaptin, RAB GTPase Binding Effector Protein 1	Protein Coding	11.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	STAT5A	Signal Transducer And Activator Of Transcription 5A	Protein Coding	11.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7514248
30	IL4	Interleukin 4	Protein Coding	11.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	CDK6	Cyclin Dependent Kinase 6	Protein Coding	10.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	MPO	Myeloperoxidase	Protein Coding	10.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8389605 8756090
33	HTT	Huntingtin	Protein Coding	10.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	RB1	RB Transcriptional Corepressor 1	Protein Coding	10.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	LUC7L2	LUC7 Like 2, Pre-MRNA Splicing Factor	Protein Coding	9.55	DISEASES inferred ¹⁴ ¹⁴
36	H2AC18	H2A Clustered Histone 18	Protein Coding	9.21	DISEASES inferred ¹⁴ ¹⁴
37	BCR	BCR Activator Of RhoGEF And GTPase	Protein Coding	7.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8818385
38	KITLG	KIT Ligand	Protein Coding	7.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9816264
39	ZRSR2	Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2	Protein Coding	7.64	DISEASES inferred ¹⁴
40	U2AF1L4	U2 Small Nuclear RNA Auxiliary Factor 1 Like 4	Protein Coding	7.59	DISEASES inferred ¹⁴
41	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	7.51	DISEASES inferred ¹⁴
42	KDM4C	Lysine Demethylase 4C	Protein Coding	7.5	DISEASES inferred ¹⁴ ¹⁴
43	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	7.09	DISEASES inferred ¹⁴
44	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	7.07	DISEASES inferred ¹⁴
45	RAB4A	RAB4A, Member RAS Oncogene Family	Protein Coding	7.07	GeneCards inferred via : Publications (show sections)
46	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	7.03	DISEASES inferred ¹⁴
47	NPM1	Nucleophosmin 1	Protein Coding	7	DISEASES inferred ¹⁴
48	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	6.98	DISEASES inferred ¹⁴
49	CD34	CD34 Molecule	Protein Coding	6.94	DISEASES inferred ¹⁴
50	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	6.94	DISEASES inferred ¹⁴

Sources

Variations for Chronic Myelomonocytic Leukemia

ClinVar genetic disease variations for Chronic Myelomonocytic Leukemia:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ETV6, FLT3	t(12;13)(p13.2;q12.2)	TRANS	Likely Pathogenic	590266		GRCh37: 12:12037520-12037521 GRCh38:

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	160282	22	11800000	24300000	Translocation		Chronic myelomonocytic leukemia
2	228217	7	75001344	75206215	Translate	HIP1	Chronic myelomonocytic leukemia
3	247204	9	129300000	140273252	Translocation		Chronic myelomonocytic leukemia

Sources

Expression for Chronic Myelomonocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.

Sources

Pathways for Chronic Myelomonocytic Leukemia

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 29)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.68	ETV6 FLT3 HIP1 JAK2 KIT NF1
2	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.26	PDGFRB KIT JAK2 FLT3 CSF3R CSF2
3	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.12	PTPN11 PDGFRB KIT JAK2 CSF3R CSF2
4	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	12.73	PTPN11 PDGFRB NF1 KIT JAK2 HIP1
5	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.72	PDGFRB KIT JAK2 FLT3 CSF3R CSF1
6	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.68	PTPN11 PDGFRB KIT JAK2 FLT3
7	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.51	PTPN11 PDGFRB KIT JAK2 CSF3R
8	NF-kappaB Signaling ³	12.45	RUNX1 KIT JAK2 GATA2
9	Malignant pleural mesothelioma ⁷⁴	12.41	PDGFRB KIT FLT3 CSF2 CSF1 ASXL1
10	Interleukin-2 family signaling ⁶⁶ Show member pathways Interleukin receptor SHC signaling ⁶⁶ Interleukin-15 signaling ⁶⁶ Interleukin-21 signaling ⁶⁶ Interleukin-3, Interleukin-5 and GM-CSF signaling ⁶⁶ Regulation of signaling by CBL ⁶⁶ Signaling by CSF1 (M-CSF) in myeloid cells ⁶⁶	12.12	CSF1 CSF2 JAK2 PTPN11
11	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.89	PTPN11 KIT JAK2
12	Tyrosine Kinases / Adaptors ³	11.88	PDGFRB KIT JAK2 FLT3
13	Gastrin signaling pathway ⁷⁴	11.85	PTPN11 KIT JAK2
14	Ras signaling ⁷⁴	11.82	PTPN11 PDGFRB NF1 KIT FLT3
15	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.79	PTPN11 KIT JAK2
16	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.73	PDGFRB KIT FLT3
17	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.62	PDGFRB KIT FLT3
18	IL3-mediated signaling events ⁶¹ Show member pathways GMCSF-mediated signaling events ⁶¹ IL5-mediated signaling events ⁶¹	11.56	PTPN11 JAK2 CSF2
19	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.43	KIT FLT3 CSF2 CSF1
20	Signaling by CSF3 (G-CSF) ⁶⁶ Show member pathways Inactivation of CSF3 (G-CSF) signaling ⁶⁶	11.41	PTPN11 JAK2 CSF3R
21	SHP2 signaling ⁶¹	11.39	PTPN11 PDGFRB JAK2
22	Signaling events mediated by PTP1B ⁶¹	11.3	PDGFRB JAK2 CSF1
23	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.09	KIT FLT3 CSF3R CSF2 CSF1
24	Pazopanib Pathway, Pharmacokinetics ⁶⁰ Show member pathways Sunitinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.08	FLT3 KIT PDGFRB
25	G-protein signaling_Rap2B regulation pathway ²²	10.88	PDGFRB KIT FLT3 CSF2 CSF1
26	Regulation of RUNX1 Expression and Activity ⁶⁶	10.86	RUNX1 PTPN11
27	S1P3 pathway ⁶¹	10.8	PDGFRB JAK2
28	Development of pulmonary dendritic cells and macrophage subsets ⁷⁴	10.72	CSF2 CSF1
29	RUNX1 regulates transcription of genes involved in differentiation of myeloid cells ⁶⁶ Show member pathways RUNX2 regulates genes involved in differentiation of myeloid cells ⁶⁶	10.62	RUNX1 CSF2

Sources

GO Terms for Chronic Myelomonocytic Leukemia

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	granulocyte macrophage colony-stimulating factor receptor complex	GO:0030526	8.92	JAK2 CSF2

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.29	PDGFRB KIT JAK2 FLT3 CSF2 CSF1
2	positive regulation of cell migration	GO:0030335	10.24	PDGFRB KIT JAK2 CSF2 CSF1
3	peptidyl-tyrosine phosphorylation	GO:0018108	10.19	FLT3 JAK2 KIT PDGFRB
4	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	10.16	PDGFRB KIT FLT3 CSF1
5	positive regulation of MAPK cascade	GO:0043410	10.15	PDGFRB KIT JAK2 FLT3
6	regulation of cell population proliferation	GO:0042127	10.02	NF1 KIT FLT3 CSF2
7	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.97	FLT3 JAK2 KIT PDGFRB
8	cytokine-mediated signaling pathway	GO:0019221	9.96	PTPN11 KIT JAK2 FLT3 CSF3R
9	platelet-derived growth factor receptor signaling pathway	GO:0048008	9.95	PTPN11 PDGFRB JAK2
10	positive regulation of phosphatidylinositol 3-kinase activity	GO:0043552	9.93	PDGFRB KIT FLT3
11	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.92	KIT JAK2 FLT3 CSF2
12	homeostasis of number of cells within a tissue	GO:0048873	9.91	PTPN11 GATA2 CSF1
13	response to fluid shear stress	GO:0034405	9.9	PDGFRB CSF2
14	myeloid progenitor cell differentiation	GO:0002318	9.88	KIT FLT3
15	response to organic cyclic compound	GO:0014070	9.88	TET2 PDGFRB JAK2 CSF1
16	positive regulation of leukocyte proliferation	GO:0070665	9.87	JAK2 CSF2
17	granulocyte-macrophage colony-stimulating factor signaling pathway	GO:0038157	9.83	CSF2 JAK2
18	mast cell proliferation	GO:0070662	9.81	KIT NF1
19	myeloid leukocyte migration	GO:0097529	9.8	CSF1 NF1
20	regulation of MAPK cascade	GO:0043408	9.72	PTPN11 NF1 KIT
21	positive regulation of response to stimulus	GO:0048584	9.61	KIT FLT3
22	hemopoiesis	GO:0030097	9.61	RUNX1 KIT GATA2 FLT3 ASXL1
23	positive regulation of protein modification process	GO:0031401	9.33	PDGFRB KIT FLT3
24	myeloid cell differentiation	GO:0030099	9.1	TET2 JAK2 GATA2 CSF2

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide hormone receptor binding	GO:0051428	9.46	PTPN11 JAK2
2	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.43	PDGFRB KIT FLT3
3	protein tyrosine kinase activity	GO:0004713	9.23	PDGFRB KIT JAK2 FLT3